SEARCH

SEARCH BY CITATION

References

  • 1
    Hayat MJ,Howlader N,Reichman ME,Edwards BK. Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program. Oncologist. 2007; 12: 20-37.
  • 2
    Hutchins LF,Unger JM,Crowley JJ,Coltman CA Jr, Albain KS. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med. 1999; 341: 2061-2067.
  • 3
    Lewis JH,Kilgore ML,Goldman DP, et al. Participation of patients 65 years of age or older in cancer clinical trials. J Clin Oncol. 2003; 21: 1383-1389.
  • 4
    Balducci L. Management of cancer in the elderly. Oncology (Williston Park). 2006; 20: 135-143; discussion 144, 146, 151-132.
  • 5
    Wedding U,Kodding D,Pientka L,Steinmetz HT,Schmitz S. Physicians' judgement and comprehensive geriatric assessment (CGA) select different patients as fit for chemotherapy. Crit Rev Oncol Hematol. 2007; 64: 1-9.
  • 6
    Extermann M,Aapro M,Bernabei R, et al. Use of comprehensive geriatric assessment in older cancer patients: recommendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG). Crit Rev Oncol Hematol. 2005; 55: 241-252.
  • 7
    Perrone F,Gallo C,Gridelli C. Re: cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial. J Natl Cancer Inst. 2002; 94: 1029-1030; author reply 1030-1021.
  • 8
    Belani CP,Fossella F. Elderly subgroup analysis of a randomized phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for first-line treatment of advanced nonsmall cell lung carcinoma (TAX 326). Cancer. 2005; 104: 2766-2774.
  • 9
    Hensing TA,Peterman AH,Schell MJ,Lee JH,Socinski MA. The impact of age on toxicity, response rate, quality of life, and survival in patients with advanced, stage IIIB or IV nonsmall cell lung carcinoma treated with carboplatin and paclitaxel. Cancer. 2003; 98: 779-788.
  • 10
    Langer CJ,Manola J,Bernardo P, et al. Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial. J Natl Cancer Inst. 2002; 94: 173-181.
  • 11
    Gridelli C,Maione P,Illiano A, et al. Cisplatin plus gemcitabine or vinorelbine for elderly patients with advanced non small-cell lung cancer: the MILES-2P studies. J Clin Oncol. 2007; 25: 4663-4669.
  • 12
    Gridelli C,Aapro M,Ardizzoni A, et al. Treatment of advanced non-small-cell lung cancer in the elderly: results of an international expert panel. J Clin Oncol. 2005; 23: 3125-3137.
  • 13
    Pfister DG,Johnson DH,Azzoli CG, et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol. 2004; 22: 330-353.
  • 14
    [No authors listed] Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. The Elderly Lung Cancer Vinorelbine Italian Study Group. J Natl Cancer Inst. 1999; 91: 66-72.
  • 15
    Fidias P,Supko JG,Martins R, et al. A phase II study of weekly paclitaxel in elderly patients with advanced non-small cell lung cancer. Clin Cancer Res. 2001; 7: 3942-3949.
  • 16
    Gridelli C,Perrone F,Gallo C, et al. Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst. 2003; 95: 362-372.
  • 17
    Ricci S,Antonuzzo A,Galli L, et al. Gemcitabine monotherapy in elderly patients with advanced non-small cell lung cancer: a multicenter phase II study. Lung Cancer. 2000; 27: 75-80.
  • 18
    Kudoh S,Takeda K,Nakagawa K, et al. Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer: results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904). J Clin Oncol. 2006; 24: 3657-3663.
  • 19
    Comella P,Frasci G,Carnicelli P, et al. Gemcitabine with either paclitaxel or vinorelbine vs paclitaxel or gemcitabine alone for elderly or unfit advanced non-small-cell lung cancer patients. Br J Cancer. 2004; 91: 489-497.
  • 20
    Frasci G,Lorusso V,Panza N, et al. Gemcitabine plus vinorelbine yields better survival outcome than vinorelbine alone in elderly patients with advanced non-small cell lung cancer. A Southern Italy Cooperative Oncology Group (SICOG) phase III trial. Lung Cancer. 2001; 34( suppl 4): S65-S69.
  • 21
    Hainsworth JD,Spigel DR,Farley C, et al. Weekly docetaxel versus docetaxel/gemcitabine in the treatment of elderly or poor performance status patients with advanced nonsmall cell lung cancer: a randomized phase 3 trial of the Minnie Pearl Cancer Research Network. Cancer. 2007; 110: 2027-2034.
  • 22
    Gridelli C,Langer C,Maione P,Rossi A,Schild SE. Lung cancer in the elderly. J Clin Oncol. 2007; 25: 1898-1907.
  • 23
    Frasci G,Comella P,Panza N, et al. Carboplatin-oral etoposide personalized dosing in elderly non-small cell lung cancer patients. Gruppo Oncologico Cooperativo Sud-Italia. Eur J Cancer. 1998; 34: 1710-1714.
  • 24
    Ramalingam SS,Dahlberg SE,Langer CJ, et al. Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599. J Clin Oncol. 2008; 26: 60-65.
  • 25
    Weiss GJ,Langer C,Rosell R, et al. Elderly patients benefit from second-line cytotoxic chemotherapy: a subset analysis of a randomized phase III trial of pemetrexed compared with docetaxel in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol. 2006; 24: 4405-4411.
  • 26
    Wheatley-Price P,Ding K,Seymour L,Clark GM,Shepherd FA. Erlotinib for advanced non-small-cell lung cancer in the elderly: an analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR. 21. J Clin Oncol. 2008; 26: 2350-2357.